News Headlines Article

After Adverse Effects, Roche Ends Trials of Diabetes Drug
New York Times

The drug maker Roche has stopped giving patients its experimental diabetes treatment taspoglutide in late-stage clinical trials because of a high rate of adverse reactions, a major blow to a drug once expected to have $2 billion-a-year potential. Roche said on Friday that the decision was based on a higher-than-expected rate of discontinuations because of gastrointestinal intolerability and as a result of serious hypersensitivity reactions experienced by some patients, according to 52-week data from the trials.